A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.

Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...

The following is a summary of “Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the ...